Fundraising FoxNeuraptive Therapeutics
Louisville, US · Founded 2017 · 2 known investors
Find your way into Neuraptive Therapeutics
Sign up to see every warm intro you have to Neuraptive Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuraptive Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.
Founders & leadership
DJ
David JacksonNamed on SEC filing
GD
Gino DiSciulloNamed on SEC filing
RH
Randy HubbellNamed on SEC filing
Board
GP
IG
Ivan GergelDirector Board of DirectorsManaging Partner and Chief Medical Officer at New Rhein Healthcare Investors, LLC
Investors · 2
Reported raises · per SEC filings
Form D private placements$29.8M disclosed across 4 rounds · 2017–2022
▶$19.5MraisedOct 2022 · 71 investors · BiotechnologyRule 506(b)
▶$19.5MraisedOct 2022 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy HubbellDirector
- Robert S RadieExecutive Officer, Director
- Greg ParekhDirector
- David PierceDirector
- Ivan GergelDirector
- David JacksonDirector
- Evan TzanisExecutive Officer
- Offering amount
- $38.1M
- Amount sold
- $19.5M
- Minimum investment
- $25K
- Sales commissions
- $1.1M
- Placement agents
- Maxim Group LLC
- First sale
- Sep 2022
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$10.2MraisedApr 2019 · 5 investors · BiotechnologyRule 506(b)
▶$10.2MraisedApr 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David JacksonExecutive Officer, Director
- Gino DiSciulloDirector
- Greg ParekhDirector
- Ivan GergelDirector
- Randy HubbellDirector
- Offering amount
- $12.5M
- Amount sold
- $10.2M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$100KraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David M JacksonExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- Minimum investment
- $100K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25KraisedAug 2017 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedAug 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David M. JacksonExecutive Officer
- Offering amount
- $1M
- Amount sold
- $25K
- Minimum investment
- $10K
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Neuraptive Therapeutics do?
- Neuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.
- Who are Neuraptive Therapeutics's investors?
- Neuraptive Therapeutics's investors include New Rhein Healthcare Investors, LLC, Central Texas Angel Network.
- How much funding has Neuraptive Therapeutics raised?
- Neuraptive Therapeutics has disclosed $29.8M raised across 4 rounds.
- Where is Neuraptive Therapeutics headquartered?
- Neuraptive Therapeutics is headquartered in Louisville, US.